Emphysema is a common pathologic manifestation of Chronic Obstructive Pulmonary Disease (COPD), the fourth leading cause of death in the United States. The most important modifiable risk factor for emphysema is chronic exposure to cigarette smoke (CS). Yet, not all smokers develop emphysema and, therefore, cellular responses to CS are important mechanisms underlying disease progression. Our long-term goal is to define the cellular responses to CS and oxidative stress that protect the lung from emphysema. We have identified a cytoprotective role for the innate immune cytokine Macrophage Migration Inhibitory (MIF). MIF decreases oxidative stress and consequences of oxidative stress (e.g. cellular senescence and apoptosis) in lung endothelial cells, and mice with a genetic deletion of Mif are susceptible to emphysema. MIF is secreted in response to CS, but, paradoxically, MIF is decreased in patients with severe COPD. Targeting MIF, or its downstream pathways, may be therapeutic. However, MIF is a pleiotropic molecule with broad regulatory effects. To translate MIF biology into therapy, it will be essential to dissect out its cytoprotective pathways. Our goal for this proposal is to determine the mechanisms through which MIF antagonizes the development of emphysema. Our preliminary data suggests MIF mediates its protective effects through its receptor CD74. Our hypothesis is MIF protects against the development of emphysema by mitigating CS-mediated endothelial senescence in a CD74 dependent manner.
In Aim 1, we will define the mechanism through which the MIF-CD74 interaction reduces endothelial senescence.
In Aim 2, we will determine the role of endothelial CD74 in regulating susceptibility to emphysema.
In Aim 3, we will determine the therapeutic potential of targeting MIF-CD74 interactions in emphysema. Completion of these aims will significantly advance our understanding of the pathogenesis of emphysema and may identify precision-based approaches based on MIF biology for treating patients with emphysema.

Public Health Relevance

This project investigates the mechanisms by which the innate immune protein Macrophage Migration Inhibitory Factor (MIF) protects against emphysema. In this proposal we will investigate the role of the MIF receptor CD74 and the downstream consequence of cellular senescence as key targets for MIF to mediate its protective effect. Successful completion of these studies may uncover novel therapeutic targets to treat emphysema.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL155948-01
Application #
10099855
Study Section
Lung Injury, Repair, and Remodeling Study Section (LIRR)
Program Officer
Lu, Jining
Project Start
2021-01-01
Project End
2025-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
1
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520